CX Institutional Purchases New Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

CX Institutional acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 77,867 shares of the company's stock, valued at approximately $2,584,000. CX Institutional owned about 0.14% of Harmony Biosciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of HRMY. Hillsdale Investment Management Inc. boosted its stake in shares of Harmony Biosciences by 0.4% in the 4th quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company's stock valued at $2,340,000 after purchasing an additional 300 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its position in Harmony Biosciences by 2.1% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock worth $704,000 after buying an additional 420 shares in the last quarter. Rhumbline Advisers lifted its position in Harmony Biosciences by 0.4% during the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company's stock worth $3,620,000 after buying an additional 485 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after buying an additional 519 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Harmony Biosciences by 1.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 62,331 shares of the company's stock worth $2,145,000 after buying an additional 678 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on HRMY shares. Oppenheimer started coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They set an "outperform" rating and a $61.00 price target on the stock. UBS Group reduced their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Needham & Company LLC reiterated a "buy" rating and issued a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Finally, Mizuho raised their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a report on Thursday, May 15th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Harmony Biosciences currently has an average rating of "Buy" and a consensus target price of $53.00.

Harmony Biosciences Stock Performance

Shares of HRMY stock traded down $0.36 during midday trading on Friday, hitting $32.97. 786,752 shares of the company were exchanged, compared to its average volume of 623,932. Harmony Biosciences Holdings, Inc. has a 52 week low of $26.47 and a 52 week high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The firm's 50 day moving average price is $32.24 and its two-hundred day moving average price is $34.05. The firm has a market capitalization of $1.89 billion, a P/E ratio of 15.63, a PEG ratio of 0.47 and a beta of 0.87.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $184.73 million during the quarter, compared to analysts' expectations of $184.26 million. During the same quarter in the previous year, the company earned $0.67 EPS. The business's revenue was up 19.5% on a year-over-year basis. As a group, equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.